Comparative Pharmacology
Head-to-head clinical analysis: PROMETHAZINE PLAIN versus ZUPLENZ.
Peer-Reviewed Evidence
Head-to-head clinical analysis: PROMETHAZINE PLAIN versus ZUPLENZ.
PROMETHAZINE PLAIN vs ZUPLENZ
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Promethazine is a phenothiazine derivative that acts primarily as a histamine H1 receptor antagonist, blocking the effects of histamine at H1 receptors. It also has anticholinergic, antiemetic, sedative, and local anesthetic properties. Its antiemetic effect is mediated through blockade of dopamine D2 receptors in the chemoreceptor trigger zone.
Competitive serotonin 5-HT3 receptor antagonist; acts centrally on the chemoreceptor trigger zone and peripherally on GI vagal nerve terminals to inhibit emesis.
25-50 mg orally, intramuscularly, or rectally every 4-6 hours as needed; maximum 100 mg per dose
8 mg administered intraorally as a single dose 1 hour before chemotherapy; may repeat once if vomiting occurs within 30 minutes after initial dose.
None Documented
None Documented
Terminal elimination half-life: 10-19 hours (average 12-15 hours). Clinical context: Requires repeated dosing for sustained effect; dosing interval typically every 6-12 hours.
Terminal elimination half-life 3.5 hours; in hepatic impairment increases to 7-9 hours
Primarily renal excretion of metabolites; less than 1% excreted unchanged. Biliary/fecal elimination accounts for approximately 25-30%.
Renal 70% unchanged, fecal 20% (including biliary metabolites), 10% metabolized
Category A/B
Category C
Antihistamine / Antiemetic
Antiemetic